Search Results

Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the development of benign tumors in the airways.

August 15, 2025

·

1 min read

·

Tristan Manalac

Press Releases

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

August 15, 2025

·

11 min read

Press Releases

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

April 16, 2025

·

4 min read

Business

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2024 financial results and business updates.

May 14, 2024

·

18 min read

BioCapital

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Precigen, Inc. (Nasdaq: PGEN) today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024.

February 6, 2024

·

2 min read

BioCapital

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Precigen, Inc. (Nasdaq: PGEN) today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 3:00 PM ET.

November 29, 2023

·

2 min read